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cycle due to continued deterioration in performance status (both 
ECOG PS 3 pre-tx).  
All patients had PD on pre-tx imaging.Table 1 summarises results.  
 
All tumours increased in size although tumour growth rates at 1 year 
were substantially lower than pre-tx in 3 patients(p=0.28, small 
patient numbers). There was no clear trend in SUVmax. Volumetric 
growth rate analysis appeared to most accurately reflect growth in 
meningiomas which often grow irregularly. 
Dosimetric analysis found that 7.4GBq administered dose equated to 
43Gy in the tumour, but a further scan at 35 hrs would have been 
helpful. Regions of 177Lu-DOTA therapy uptake mirrored regions of 
tracer avidity on 68Ga-DOTA scans.  
Conclusions: 177Lu-DOTA is well tolerated and may reduce growth 
rates in some patients with advanced meningioma. Larger studies in 
patients of good PS are required. As 177Lu emits γ rays, dosimetric 
evaluation of tumour uptake is possible and prescribed dose could be 
individually tailored to deliver a desired absorbed dose, however, 
further work is required to assess reliability of dose estimation.  
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Purpose/Objective: As paediatric medulloblastoma (MB) is a relatively 
rare disease, it is important to extract the most information possible 
on its response to therapy from trials and cohort studies. Here, a 
framework is developed for modeling tumor control with multiple 
modes of failure and time-to-progression, using pattern of failure data 
from published standard-risk MB series. 
Materials and Methods: Using a meta-analysis approach, data from 
reports on outcome after radio-chemotherapy in standard-risk MB 
published after 1990 and containing information on pattern of relapse 
were selected. Out of 287 screened records, 12 were included to 
derive a tumor control dose-response model addressing failures in the 
high-dose boost volume and the elective craniospinal volume. Failures 
in the boost and elective volume were assumed to be statistically 
independent and failures diagnosed as simultaneous were assumed to 
have originated in the primary site and subsequently spread to the 
elective volume. Here, we used a mixture model to describe the 
freedom from progression (FFP). The time-to-progression distribution 
was based on Kaplan-Meier estimates of 5-year event-free survival 
from two large randomized MB trials (SIOP-PNET-4 from 2012 and 
Packer et al. from 2006). The uncertainty in the estimated 5-year FFP 
was estimated by Monte Carlo sampling (2000 samples) over the 
statistical uncertainty in the input data of the dose-response model. 
Results: The estimated values of 5-year FFP, and 95% confidence 
intervals (CIs) were 69% (56-81%), 77% (74-81%), 79% (77-82%) and 82% 
(78-84%) for CSI doses of zero, 18, 24 and 36 Gy respectively, while 
keeping the boost dose constant at 54 Gy. The uncertainty in FFP 
estimates were considerably larger for craniospinal doses below 18 Gy 
compared to between 24 and 36 Gy, reflecting the limited amount of 
data in the lower dose range. 
 
Figure 1. Estimated FFP for three scenarios, zero Gy craniospinal 
irradiation (CSI), 24 Gy CSI or 36 Gy CSI. Vertical bars represent the 
95% CIs for FFP at 5 years after diagnosis (displaced slightly in the 
graph for visualization), based on 2000 Monte Carlo samples. 
 
Conclusions: We show that while keeping the boost dose constant, 
varying the CSI dose only slightly alters the estimated outcome. 
Omitting the CSI however, shows a clear drop in the estimated FFP. 
Using this model, a post-hoc power calculation for the two treatment 
regimens compared in the recently published SIOP-PNET-4 trial yields 
a statistical power, given the trial sample size, at only 13%, which 
could explain the negative result of that trial. As illustrated in Figure 
1, there are large gaps in the knowledge of the efficacy of very low 
CSI doses; therefore the tumor control estimates at low doses should 
be interpreted with caution.  
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Purpose/Objective: To evaluate the efficacy and outcome of using a 
combination of 4 - 6 cycles of Doxorubicin, Bleomycin, Vinblastine, 
and Dacarbazine (ABVD) chemotherapy (CTh) and involved field 
radiation therapy (IFRT) in the management of paediatric early stage 
unfavorable Hodgkin's lymphoma (HL). 
Materials and Methods: Seventy children less than 18yrs of age with 
early stage unfavourable HL treated with 4-6 cycles of ABVD followed 
by IFRT were included in this analysis. There were 59 (84.3%) males 
and 11 (15.7%) females. The commonest histological subtype was 
mixed cellularity. Majority of the patients (54%) had stage IIAX 
disease. Based on response to CTh the radiation doses were 19.8Gy/ 
11 fractions and 30.6Gy/ 17 fractions for patients with complete 
response (CR) and partial response (PR) respectively. 
Results: After a median follow-up of 60 months, the 10 year disease 
free survival (DFS) and overall survival (OS) were 94% and 97% 
respectively. On univariate analysis prognostic factors found to have 
significant impact on DFS were, bulky disease (p=0.003), nodular 
lymphocyte predominant histology (p=0.003) and stage of disease 
(p=0.045).None of the prognostic factors had a significant impact on 
OS. On multivariate analysis using Cox regression model, none of the 
prognostic factors were found to have a significant impact on DFS and 
OS.There was no difference between 4 and 6 cycles of ABVD in terms 
of acute pulmonary, haematological and other treatment related 
acute toxicities. Grade II dermatitis for pts. receiving RTh doses more 
than 25Gy or less were 20% and 14.6% respectively, while the 
corresponding incidence of mucositis was 13.3% and 3.5% respectively. 
Conclusions: Our study supports the current standard of care for 
paediatric early stage unfavourable HL of using four cycles of ABVD 
CTh followed by IFRT. This combination results in optimal outcomes in 
terms of disease control and treatment related toxicities.  
   
 
 
 
 
 
 
 
 
